Corporate Profile

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is a patient-focused, innovative, commercial-stage, global biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies in order to generate a broad pipeline of innovative marketed products and product candidates. We have also built an in-house team with strong product discovery and translational research capabilities and are establishing a pipeline of proprietary product candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide.

INVESTOR HIGHLIGHTS
Corporate Mission

Corporate Mission

Investor Presentation

Investor Presentation

Our Pipeline

Our Pipeline

Stock Quote

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent Press Releases

Zai Lab Announces Primary Listing on the Main Board of The Stock Exchange of Hong Kong Limited

Jun 27, 2022

Zai Lab Announces Breakthrough Therapy Designations Granted for Repotrectinib in China

Jun 10, 2022

Zai Lab and Novocure Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

Jun 03, 2022